- Home
- RARE vs EOSE Comparison
RARE vs EOSE Comparison
Compare RARE & EOSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | EOSE |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.6B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | RARE | EOSE |
|---|---|---|
| Price | $34.86 | $12.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 7 |
| Target Price | ★ $85.20 | $12.79 |
| AVG Volume (30 Days) | 1.5M | ★ 17.2M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $630,598,000.00 | $63,458,000.00 |
| Revenue This Year | $19.09 | $881.87 |
| Revenue Next Year | $20.62 | $230.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 20.63 | ★ 324.10 |
| 52 Week Low | $25.81 | $3.07 |
| 52 Week High | $46.50 | $19.86 |
Technical Indicators
Market Signals| Indicator | RARE | EOSE |
|---|---|---|
| Relative Strength Index (RSI) | 52.17 | 44.74 |
| Support Level | $32.64 | $12.22 |
| Resistance Level | $36.81 | $16.49 |
| Average True Range (ATR) | 1.60 | 1.34 |
| MACD | -0.29 | -0.21 |
| Stochastic Oscillator | 28.83 | 15.79 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.